All sponsors

Praxis Precision Medicines

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS8
PHASE 3 / 2-36
RECRUITING3
READOUTS ≤12 MONTHS3
Open Praxis Precision Medicines on the live radar map →
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
30mg PRAX-628
NCT06908356
P2RecruitingFocal Onset Seizure; Primary Generalized Epilepsy502025-07
60 mg ulixacaltamide
NCT06087276
P3RecruitingEssential Tremor10002025-10-10
EMBOLD
NCT05818553
P2/3Active, not recruitingSCN2A Encephalopathy; SCN8A Encephalopathy772025-11-12 (+26 mo)
PRAX-222 - Initial Dose
NCT05737784
P1/2Active, not recruitingSCN2A-DEE; Epilepsy602026-04-01 (+9 mo)
EMERALD
NCT07010471
P3Active, not recruitingDevelopmental and Epileptic Encephalopathy 11602026-12 (+8 mo)
1mg elsunersen
NCT07019922
P3RecruitingEpileptic Encephalopathy; SCN2A Encephalopathy402026-12 (+6 mo)
POWER2
NCT07505004
P3Active, not recruitingFocal Epilepsy3002027-01
vormatrogine
NCT07287163
P3Enrolling by invitationEpilepsy, Tonic-Clonic; Focal Seizure7002028-05-31